Marchex, Inc. (MCHX) is a small-cap provider of AI-based conversational intelligence and analytics that helps companies in automotive, home services, healthcare, real estate, and advertising extract insights from customer communications. The stock has been volatile, and the central question is whether it can reclaim the $2.00 level.
Marchex does not have enough credible, current analyst price targets to form a meaningful aggregate. The only verified price target is a $4.00 Buy rating from Northland Securities analyst Michael Latimore, reiterated in July and August 2026. Because a single target cannot support a reliable consensus, this article does not treat $4.00 as the central objective. Instead, the $2.00 level comes from identifiable public market discussion: it is a psychological price level sitting just under the stock's 52-week high of approximately $2.03, a prior high that represents a natural technical milestone and resistance zone.
The shares traded near $1.31 in mid-October 2026, within a 52-week range of roughly $1.15 to $2.03. Moving from $1.31 to $2.00 implies upside of about 53%, which qualifies as a very large required move. The path would require both a fundamental re-rating and a technical breakout: the stock currently sits below its 50-day moving average (about $1.57) and 200-day moving average (about $1.61), with a beta near 1.9 indicating above-market volatility. Trailing twelve-month revenue was roughly $44 million with a net loss near $5.5 million and a price-to-sales (P/S) ratio around 1.5.
Management has positioned Marchex at an "AI inflection point," shifting from standalone analytics toward bundled AI-powered solutions that combine insights, automated actions, and verifiable outcomes. The pending acquisition of Archenia, announced in May 2026, could lift the combined revenue run rate toward roughly $15 million per quarter (about $60 million annualized) with projected growth of 15–20%. Adjusted EBITDA guidance has been raised, with Q3 expected "in the $2 million range or more" and margins trending toward 10% or higher. The balance sheet is also conservative, with low leverage and cash near $8–9 million.
Marchex has yet to achieve sustained GAAP profitability, and revenue has contracted over multiple years. Roughly 90% of revenue comes from its top 100 customers, creating concentration risk, and the migration of clients to its new Engage platform has pressured revenue run rates. The Archenia deal carries integration and execution risk, and the stock's thin average volume (roughly 30,000–35,000 shares) and high beta can amplify downside. With only one analyst price target, there is little independent confirmation of fair value.
The 52-week low near $1.15 is the most important downside reference, while $2.00–$2.03 marks the ceiling set by the prior high and a psychological round number. The 50-day (about $1.57) and 200-day (about $1.61) moving averages now sit above the price, acting as overhead supply. A durable reclaim of $1.60–$1.65 would likely be an early signal of improving trend structure before any test of $2.00.
The single analyst target reflects a roughly 12-month research horizon, but the $2.00 milestone has no fixed time frame. Investors should watch the next earnings report (estimated around November 12, 2026), the closing and integration of the Archenia acquisition, sequential revenue and adjusted EBITDA progress, any new analyst initiation or target revisions, and whether the stock can hold above its moving averages.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual scanning. For a thinly traded, volatile name like Marchex, automated signal monitoring can help investors stay current on momentum shifts and emerging technical setups.
The $2.00 target is a technical milestone tied to Marchex's 52-week high and a round-number resistance level, not a published analyst consensus. Reaching it would require a roughly 53% advance, a very large move that hinges on successful execution of the AI bundle strategy and the Archenia acquisition, a return to revenue growth, and expansion toward sustainable profitability. Persistent losses, customer concentration, and weak technical structure below the moving averages are the principal obstacles. A single $4.00 analyst target sits well above this level, underscoring the wide uncertainty around the name. Whether $2.00 is attainable depends on fundamentals and sentiment improving in tandem, and investors should monitor earnings, deal integration, and technical levels rather than assume any outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that MCHX and EVC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MCHX and EVC's prices will move in lockstep.
| Ticker / NAME | Correlation To MCHX | 1D Price Change % | ||
|---|---|---|---|---|
| MCHX | 100% | -0.78% | ||
| EVC - MCHX | 33% Poorly correlated | -0.32% | ||
| STGW - MCHX | 20% Poorly correlated | -0.22% | ||
| BOC - MCHX | 20% Poorly correlated | -0.48% | ||
| NCMI - MCHX | 20% Poorly correlated | -3.41% | ||
| ABLV - MCHX | 20% Poorly correlated | +4.46% | ||
More | ||||